M&A

Stryker to pay $700m for Novadaq
Mass Device
Mon, 06/19/17 - 11:44 pm
Stryker
M&A
Medical Imaging
Novadaq Technologies
devices
Post-boom biotech still has plenty of upbeat trends to boast about
Endpoints
Mon, 06/19/17 - 07:15 am
biotech
funding
M&A
3 Biotech Stocks That Could Become M&A Targets
Motley Fool
Sat, 06/17/17 - 03:05 pm
biotech
M&A
Mallinckrodt
Tesaro
Incyte
Johnson & Johnson closes $30B Actelion buyout
Drug Delivery Business News
Fri, 06/16/17 - 10:16 am
JNJ
Actelion
M&A
5 Things You Didn't Know About Eli Lilly and Co
Motley Fool
Thu, 06/15/17 - 09:47 am
Eli Lilly
drug pricing
M&A
animal health
Is Mallinckrodt in Talks to Be Sold?
Motley Fool
Tue, 06/13/17 - 10:14 pm
Mallinckrodt
M&A
Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space
TheStreet.com
Tue, 06/13/17 - 05:48 pm
drug pricing
patents
patent cliffs
M&A
generics
Sanofi, Gilead said to be eyeing potential $10B deal for prime cancer target Tesaro
Fierce Pharma
Mon, 06/12/17 - 09:40 pm
Sanofi
Gilead Sciences
Tesaro
M&A
What Valeant Pharmaceuticals' Latest Sale Means (and Doesn't Mean) for Investors
Motley Fool
Sun, 06/11/17 - 09:19 am
Valeant Pharmaceuticals
investors
M&A
iNova
Johnson & Johnson wins last regulatory nod needed for Actelion acquisition
Drug Delivery Business News
Sat, 06/10/17 - 12:14 pm
JNJ
Actelion
M&A
EU
Europe
Valeant's iNova Sale Is Much Ado About Nothing
Seeking Alpha
Fri, 06/9/17 - 10:02 am
Valeant Pharmaceuticals
iNova
M&A
Why Valeant Pharmaceuticals Intl. Inc. Jumped Higher Today
Motley Fool
Thu, 06/8/17 - 09:59 pm
Valeant Pharmaceuticals
M&A
iNova
Johnson & Johnson’s $30B buyout suffers setback as Actelion antibiotic fails in one phase 3, succeeds in another
Fierce Biotech
Thu, 06/8/17 - 09:38 am
JNJ
Actelion
clinical trials
M&A
antibiotics
cadazolid
Allergan picks up aesthetic device dev Keller Medical
Mass Device
Wed, 06/7/17 - 07:01 pm
Allergan
devices
M&A
Keller Medical
AstraZeneca to sell Zomig migraine drug rights
Marketwatch
Wed, 06/7/17 - 12:15 pm
AstraZeneca
Zomig
migraines
Grunenthal
M&A
Pfizer's $14B Medivation deal's now a cautionary M&A tale, thanks to ASCO: analyst
Fierce Pharma
Tue, 06/6/17 - 09:41 am
Pfizer
Medivation
M&A
ASCO 2017
Instant Analysis: Mallinckrodt Considering Sale of Generics Unit
Motley Fool
Thu, 06/1/17 - 08:48 am
Mallinckrodt
generics
M&A
Thermo Fisher on an Acquisition Spree, Competition Rife
Yahoo/Zacks.com
Wed, 05/31/17 - 09:18 am
Thermo Fisher
M&A
devices
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Fierce Biotech
Tue, 05/30/17 - 06:20 pm
JNJ
Protagonist Therapeutics
M&A
Crohn's Disease
PTG-200
Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio
Endpoints
Tue, 05/30/17 - 10:40 am
Sanofi
Immunogen
oncology
M&A
isatuximab
Multiple Myeloma

Pages